13838-78-3

Basic information

• Product Name: 5-Methyl-1,3-thiazole-2-carboxaldehyde
• Synonyms: 5-Methylthiazole-2-carboxaldehyde;2-Formyl-5-methyl-1,3-thiazole;5-methyl-2-thiazolecarboxaldehyde;5-Methyl-1,3-thiazole-2-carboxaldehyde;5-methyl-1,3-thiazole-2-carbaldehyde
• CAS NO: 13838-78-3
• Molecular Formula: C₅H₅NOS
• Molecular Weight: 127.1643
• Product Categories: Thiazoles, Isothiazoles & Benzothiazoles;Aldehydes;Thiazoles, Isothiazoles &Benzothiazoles
• Mol File: 13838-78-3.mol

Chemical Properties

• Boiling Point: 236.0℃
• Flash Point: 96.5℃
• Appearance: /
• Density: 1.270
• Vapor Pressure: 0.074mmHg at 25°C
• Refractive Index: 1.601
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 0.92±0.10(Predicted)
• CAS DataBase Reference: 5-Methyl-1,3-thiazole-2-carboxaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Methyl-1,3-thiazole-2-carboxaldehyde(13838-78-3)
• EPA Substance Registry System: 5-Methyl-1,3-thiazole-2-carboxaldehyde(13838-78-3)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 13838-78-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
5-Methyl-1,3-thiazole-2-carboxaldehyde is used as a synthetic intermediate for the production of various pharmaceuticals. Its role in the synthesis process is crucial for creating a range of medications that can address different health conditions.
Used in Organic Compounds Production:
5-Methyl-1,3-thiazole-2-carboxaldehyde is used as a synthetic intermediate in the creation of other organic compounds. Its versatility in chemical reactions allows for the development of a wide array of products with various applications in different industries.
Safety Precautions:
5-Methyl-1,3-thiazole-2-carboxaldehyde is used as a hazardous chemical that requires special handling and safety measures. Its flammability and irritant properties necessitate the implementation of proper protective equipment and procedures to ensure the safety of those working with this substance.

InChI:InChI=1/C5H5NOS/c1-4-2-6-5(3-7)8-4/h2-3H,1H3

Upstream product

• 7305-71-7 5-methyl-2-thiazol-2-amine 
• 75-17-2 formaldoxime 
• 68-12-2 N,N-dimethyl-formamide 
• 3581-89-3 5-methylthiazole 
• 4394-85-8 4-morpholinecarboxaldehyde 
• 41731-23-1 2-bromo-5-methyl-1,3-thiazole 

Downstream Products

• 108487-89-4 5-methyl-thiazole-2-carbaldehyde-(4-phenyl-thiazol-2-ylhydrazone) 
• 13750-90-8 N-(5-methyl-thiazol-2-ylmethylene)-aniline 
• 454483-82-0 5-methyl-thiazole-2-carbaldehyde oxime 
• 202932-04-5 (5-methyl-1,3-thiazol-2-yl)methanol 
• 100516-71-0 5-methyl-thiazole-2-carbonitrile 
• 921145-14-4 N-methyl-1-(5-methylthiazol-2-yl)methanamine 
• 921145-23-5 2-(chloromethyl)-5-methylthiazole 

Relevant articles and documents

HEPATITIS B VIRUS SURFACE ANTIGEN INHIBITOR

10-oxo-6,1-dihydrobenzo[e]pyrido[1,2-c][1,3]oxazine-9-carboxylic acid derivatives of formula (I) as hepatitis B surface antigen inhibitors or pharmaceutically acceptable salts thereof, and uses of a compound of formula (I) or pharmaceutically acceptable salts thereof and pharmaceutical compositions thereof in preparation of medicaments for treatment of viral hepatitis B.

THIENO[3,2-B] PYRROLE[3,2-D]PYRIDAZINONE DERIVATIVES AND THEIR USE AS PKM2 DERIVATIVES FOR THE TREATMENT OF CANCER, OBESITY AND DIABETES RELATED DISORDERS

Described herein are compounds that regulate pyruvate kinase activity, pharmaceutical compositions and methods of use thereof. These compounds are represented by Formula (I) wherein R2, L1-L2, U1-U7, m, ring A, and Q are as defined herein.

SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF

Compounds, compositions and methods are described for inhibiting the TRPC5 ion channel and disorders related to TRPC5.

SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF

Compounds, compositions and methods are described for inhibiting the TRPC5 ion channel and disorders related to TRPC5.

(3-HYDROXY-4-AMINO-BUTAN-2-YL) -3- (2-THIAZOL-2-YL-PYRROLIDINE-1-CARBONYL) BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BETA-SECRETASE INHIBITORS FOR TREATING

The present invention provides novel beta-secretase inhibitors and methods for their use, including methods of treating of Alzheimer's disease. (Formula)

Non-covalent thrombin inhibitors featuring P3-heterocycles with P1-monocyclic arginine surrogates

Investigations on P2-P3-heterocyclic dipeptide surrogates directed towards identification of an orally bioavailable thrombin inhibitor led us to pursue novel classes of achiral, non-covalent P1-arginine derivatives. The design, synthesis, and biological activity of inhibitors NC1-NC30 that feature three classes of monocyclic P1-arginine surrogates will be disclosed: (1) (hetero)aromatic amidines, amines and hydroxyamidines, (2) 2-aminopyrazines, and (3) 2-aminopyrimidines and 2-aminotetrahydropyrimidines.

Substituted heterocyclylisoquinolinium salts and compositions and method of use thereof

Substitutued heterocyclylisoquinolinium salts, pharmaceutical compositions containing them and methods for the treatment or prevention of neurodegenerative disorders or neurotoxic injuries utilizing them.